Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

800 - Response to bortezomib in newly diagnosed multiple myeloma- a single centre experience from India


19 Dec 2015


Poster presentation 1


Varun Rajan


Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526


V. Rajan1, G. N2, S.G. Nair2

Author affiliations

  • 1 Medical Oncology, Regional Cancer Centre Thiruvananthapuram/Trivandrum, 695011 - Thiruvananthapuram (Trivandrum)/IN
  • 2 Medical Oncology, Regional Cancer Centre Thiruvananthapuram/Trivandrum, Thiruvananthapuram (Trivandrum)/IN


Abstract 800


To study the clinical presentation and response to treatment in patients with newly diagnosed myeloma who were treated with Bortezomib containing regimens


This is a retrospective analysis of patients diagnosed as multiple myeloma during the period 2011- 2013 in the department of Medical Oncology at Regional Cancer Centre, Trivandrum, India and have received chemotherapy with Bortezomib based regimen as frontline. These patients were followed up till date.


Forty one patients diagnosed as multiple myeloma during the period 2011-2013 received front line Bortezomib based chemotherapy. There were 23 males and 18 females. The median age at presentation was 52 years. The predominant symptom was bone pain in 38 patients. Twenty four patients had a Haemoglobin <10 gm% and 11 had raised serum creatinine. Fifteen patients had ISS stage 1 disease (International Staging System), 9 patients had ISS 2, and 16 had ISS 3. Twenty five patients had IgG myeloma, 8 had IgA, 6 patients had only light chain disease and 2 were non secretory. Forty one patients received 6 cycles of Bortezomib based chemotherapy for Induction. Peripheral blood stem cell transplantation was done in 6 as consolidation. Twenty eight patients achieved very good partial response (VGPR) or more after induction. Six patients had progressive disease and five patients died. The median survival of the series is 36 months and the 2 year survival is 85%.


Bortezomib based chemotherapy is highly effective in newly diagnosed myeloma resulting in more than VGPR in 74% of patients in this study. IgG myeloma was the predominant subtype (60%). Bortezomib based induction therapy significantly improved Overall Survival (OS) in previously untreated patients. 85% of patients attained 24 months of OS and median survival of the series was 36 months.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings